CYP1A1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Alpha-Naphthoflavone (SCHEMBL121594)	1.00	14/20
SCHEMBL145083	0.76	14/20
SCHEMBL113300	0.55	10/20
SCHEMBL113301	0.55	10/20
SCHEMBL96291	0.70	9/20
SCHEMBL83267	0.56	9/20
SCHEMBL83322	0.56	9/20
SCHEMBL151090	0.51	9/20
SCHEMBL151091	0.51	9/20
SCHEMBL140807	0.56	8/20
SCHEMBL126703	0.54	8/20
SCHEMBL167090	0.54	8/20
SCHEMBL82827	0.49	8/20
SCHEMBL98657	0.48	8/20
Kaempferol (SCHEMBL18817)	1.00	7/20
Myricetin (SCHEMBL19302)	1.00	7/20
Quercetin (SCHEMBL19723)	1.00	7/20
Galangin (SCHEMBL117225)	1.00	7/20
Quercetin (SCHEMBL118425)	1.00	7/20
Quercetin (SCHEMBL22103)	0.97	7/20

Clinical trials — most relevant to CYP1A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies	PHASE4	RECRUITING
Comparative Effects of Azithromycin, Telithromycin and Levofloxacin on Drug Metabolizing Enzymes	PHASE4	COMPLETED
Role of Antioxidants Supplementation in Chronic Pancreatitis	PHASE3	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Oral Cannabidiol for Opioid Withdrawal	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma	PHASE2	NOT_YET_RECRUITING
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis	PHASE2	ACTIVE_NOT_RECRUITING
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer	PHASE2	COMPLETED
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer	PHASE1	COMPLETED
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers	PHASE1	COMPLETED
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)	PHASE1	COMPLETED
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease	PHASE1	COMPLETED
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer	PHASE1	COMPLETED
AZD1981 Midazolam CYP4503A Induction Study	PHASE1	COMPLETED
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab	PHASE1	COMPLETED
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies	PHASE1	UNKNOWN
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac	EARLY_PHASE1	RECRUITING
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment	nan	RECRUITING
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis	nan	COMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Molecular Epidemiology of Dioxin-Related Illness in Seveso	nan	COMPLETED
Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics	nan	COMPLETED
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics	nan	COMPLETED
Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC	nan	NOT_YET_RECRUITING
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk	nan	COMPLETED
Effects of Genotype on CYP2C9 Drug Interactions	nan	COMPLETED
Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients	nan	COMPLETED
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline	nan	COMPLETED
Impact of OCT1 and CYP2D6 Genotypes on Pharmacokinetics of Berberine in Healthy Volunteers	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP1A1 binder may also engage these)

Protein	Name	Similarity
P00185	—	1.000	P00185 →
Q6GUR1	—	1.000	Q6GUR1 →
P33616	—	1.000	P33616 →
Q5KQT7	—	1.000	Q5KQT7 →
Q06367	—	0.999	Q06367 →
P56590	—	0.998	P56590 →
P00184	—	0.998	P00184 →
Q3LFU0	—	0.998	Q3LFU0 →
P79761	—	0.997	P79761 →
Q00557	—	0.996	Q00557 →
Q92116	—	0.995	Q92116 →
Q92100	—	0.994	Q92100 →
P05176	—	0.993	P05176 →
P56591	—	0.992	P56591 →
Q9YH64	—	0.992	Q9YH64 →
Q92095	—	0.991	Q92095 →
O42430	—	0.991	O42430 →
Q92109	—	0.990	Q92109 →
Q92110	—	0.990	Q92110 →
O42231	—	0.990	O42231 →
O42457	—	0.990	O42457 →
O77809	—	0.989	O77809 →
Q92039	—	0.989	Q92039 →
P79716	—	0.989	P79716 →
Q9W683	—	0.989	Q9W683 →
Q6JZS3	—	0.989	Q6JZS3 →
Q5KQT6	—	0.988	Q5KQT6 →
CYP1A2	Cytochrome P450 1A2	0.986	landscape →
P79760	—	0.984	P79760 →
Q4H4C3	—	0.983	Q4H4C3 →